NYSE · NVS
Novartis AG
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for NVS has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $2.23 | $2.31 | $2.16 | 5 |
| Mar 2027 | $2.29 | $2.35 | $2.20 | 3 |
| Jun 2027 | $2.54 | $2.56 | $2.52 | 3 |
| Sep 2027 | $2.55 | $2.65 | $2.45 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · The Motley Fool- Zacks · Oct 29, 2:11 PM EDTINCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedIncyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
- Zacks · Oct 28, 9:33 AM EDTHow Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.
- RTTNews · Oct 28, 8:21 AM EDTMonte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock Up(RTTNews) – Monte Rosa Therapeutics, Inc. (GLUE) announced that Novartis has initiated a second Phase 2 clinical study of MRT-6160 (DDY391), its investigational VAV1-directed molecular glue degrader, in participants with active moderate to severe psoriatic arthritis.
- Zacks · Oct 28, 7:55 AM EDTThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThe Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- Zacks · Oct 28, 3:29 AM EDTThe Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVieEli Lilly, Novartis, Johnson & Johnson and AbbVie advance arthritis treatment portfolios through strong drug sales, clinical progress and regulatory expansions.
- RTTNews · Oct 28, 3:02 AM EDTCardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial(RTTNews) – Shares of Cardiff Oncology, Inc. (CRDF) fell 5.70% in after-hours trading on Tuesday after the clinical-stage biotechnology company announced Leila Alland's appointment as interim chief medical officer (CMO).
- MarketBeat · Oct 27, 6:04 PM EDTWhat Novartis (NVS) Said on Its Q3 Earnings CallVIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.
- The Motley Fool · Oct 27, 12:46 PM EDTNovartis (NVS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Oct 27, 11:16 AM EDT4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialLLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
- Zacks · Oct 27, 10:49 AM EDTNVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues MissNovartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
- Zacks · Oct 27, 8:30 AM EDTNovartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Zacks · Oct 27, 7:46 AM EDTThe Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREPIntel, Novartis, Itau Unibanco and AMREP face distinct growth opportunities and risks, from AI expansion and drug sales to banking growth and real estate development.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Novartis AG from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.